

Tildipirosin

Catalog No: tcsc3296



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

328898-40-4

Formula:

$C_{41}H_{71}N_3O_8$

Pathway:

Anti-infection

Target:

Bacterial

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:


734.02

Product Description

Tildipirosin, a long-acting macrolide, has antibiotic activity.

In Vitro: Tildipirosin exhibits the inhibitory effect on *C. coli* species, and 23 of 31 (74%) isolates have MICs of 8 or 16 µg/mL while 8 of 31 (26%) have MIC >256 µg/mL. MICs against *C. jejuni* are 8-64 µg/mL. Tildipirosin against *S. enterica* and *E. coli* are 2-8 µg/mL^[1]. Tildipirosin inhibits the treponeme isolates from CODD lesions from 19 sheep, with MIC90 of 0.0469 mg/L^[3]. The *P. multocida* B130 clones show the MIC of 0.25 mg/L for tildipirosin. The 10 *P. multocida* isolates that carry only erm(42) exhibit MIC of 16-32 mg/L for tildipirosin. The single *M. haemolytica* that harbours only erm(42) shows MIC of 32 mg/L for tildipirosin^[4].

In Vivo: The mean percentage of lung consolidation for tildipirosin (4 mg/kg, s.c.)-treated calves is significantly lower than those for tulathromycin-treated and control calves. Metaphylactic administration of tildipirosin to calves 5 days prior to H somni challenge prevents subsequent culture of the pathogen from bronchial secretions and is more effective in minimizing clinical disease and lung lesions than is metaphylactic administration of tulathromycin^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!